1. Market Research
  2. > Diabetic Complications - Pipeline Review, H2 2013

Diabetic Complications - Pipeline Review, H2 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 65 pages

Diabetic Complications - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Diabetic Complications - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Complications, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Complications. Diabetic Complications - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Diabetic Complications.
- A review of the Diabetic Complications products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Diabetic Complications pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Diabetic Complications.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Diabetic Complications pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Diabetic Complications - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Diabetic Complications Overview 7
Therapeutics Development 8
Pipeline Products for Diabetic Complications - Overview 8
Pipeline Products for Diabetic Complications - Comparative Analysis 9
Diabetic Complications - Therapeutics under Development by Companies 10
Diabetic Complications - Therapeutics under Investigation by Universities/Institutes 12
Diabetic Complications - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Diabetic Complications - Products under Development by Companies 16
Diabetic Complications - Products under Investigation by Universities/Institutes 17
Diabetic Complications - Companies Involved in Therapeutics Development 18
Tissue Repair Company 18
Torrent Pharmaceuticals Limited 19
Evolva SA 20
Diabetology Limited 21
GenKyoTex S.A. 22
Noxxon Pharma AG 23
MacuCLEAR, Inc. 24
Amunix, Inc. 25
BiogenCell Ltd. 26
Endocrine Technology, L.L.C. 27
Diabetic Complications - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Target 29
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Assessment by Therapeutic Class 38
Drug Profiles 41
EV-077 - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
NOX-E-36 - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
GKT-137831 - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
TRC-4186 - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
DIOHF - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
Oral C-Peptide Analogs - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
Migration Stimulating Factor - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
Glyoxalase-1 Therapy - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
ETR-001 - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
MG-132 - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
BC-1 - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
AMX-888 - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
MC-4001 - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
Diabetic Complications - Recent Pipeline Updates 58
Diabetic Complications - Dormant Projects 63
Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 65
Disclaimer 65



List of Tables

Number of Products under Development for Diabetic Complications, H2 2013 8
Number of Products under Development for Diabetic Complications - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 11
Number of Products under Investigation by Universities/Institutes, H2 2013 12
Comparative Analysis by Clinical Stage Development, H2 2013 13
Comparative Analysis by Early Stage Development, H2 2013 14
Comparative Analysis by Unknown Stage Development, H2 2013 15
Products under Development by Companies, H2 2013 16
Products under Investigation by Universities/Institutes, H2 2013 17
Diabetic Complications - Pipeline by Tissue Repair Company, H2 2013 18
Diabetic Complications - Pipeline by Torrent Pharmaceuticals Limited, H2 2013 19
Diabetic Complications - Pipeline by Evolva SA, H2 2013 20
Diabetic Complications - Pipeline by Diabetology Limited, H2 2013 21
Diabetic Complications - Pipeline by GenKyoTex S.A., H2 2013 22
Diabetic Complications - Pipeline by Noxxon Pharma AG, H2 2013 23
Diabetic Complications - Pipeline by MacuCLEAR, Inc., H2 2013 24
Diabetic Complications - Pipeline by Amunix, Inc., H2 2013 25
Diabetic Complications - Pipeline by BiogenCell Ltd., H2 2013 26
Diabetic Complications - Pipeline by Endocrine Technology, L.L.C., H2 2013 27
Assessment by Monotherapy Products, H2 2013 28
Number of Products by Stage and Target, H2 2013 31
Number of Products by Stage and Mechanism of Action, H2 2013 33
Number of Products by Stage and Route of Administration, H2 2013 35
Number of Products by Stage and Molecule Type, H2 2013 37
Number of Products by Stage and Therapeutic Class, H2 2013 40
Diabetic Complications Therapeutics - Recent Pipeline Updates, H2 2013 58
Diabetic Complications - Dormant Projects, H2 2013 63



List of Figures

Number of Products under Development for Diabetic Complications, H2 2013 8
Number of Products under Development for Diabetic Complications - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 10
Comparative Analysis by Clinical Stage Development, H2 2013 13
Comparative Analysis by Early Stage Products, H2 2013 14
Comparative Analysis by Unknown Stage Development, H2 2013 15
Assessment by Monotherapy Products, H2 2013 28
Number of Products by Top 10 Target, H2 2013 29
Number of Products by Stage and Top 10 Target, H2 2013 30
Number of Products by Top 10 Mechanism of Action, H2 2013 32
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 33
Number of Products by Top 10 Route of Administration, H2 2013 34
Number of Products by Stage and Top 10 Route of Administration, H2 2013 35
Number of Products by Top 10 Molecule Type, H2 2013 36
Number of Products by Stage and Top 10 Molecule Type, H2 2013 37
Number of Products by Top 10 Therapeutic Class, H2 2013 38
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 39



Companies Mentioned

Tissue Repair Company
Torrent Pharmaceuticals Limited
Evolva SA
Diabetology Limited
GenKyoTex S.A.
Noxxon Pharma AG
MacuCLEAR, Inc.
Amunix, Inc.
BiogenCell Ltd.
Endocrine Technology, L.L.C.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.